Case Report

J Rheum Dis 2012; 19(3): 147-151

Published online June 30, 2012

© Korean College of Rheumatology

장피부 누공을 동반한 베체트 장염 환자를 Adalimumab으로 치료한 1예

오일환1ㆍ김진옥1ㆍ변영재1ㆍ성윤경1,2ㆍ최찬범1,2ㆍ김태환1,2ㆍ전재범1,2ㆍ엄완식1,2

한양대학교 의과대학 내과학교실1, 류마티스병원 류마티스내과2

A Case of Intestinal Behçet's Disease Complicated Enterocutanous Fistula with a Good Response to Adalimumab

IL Hwan Oh1, Jin Ok Kim1, Young Jae Byun1, Yoon-Kyoung Sung1,2, Chan-Bum Choi1,2, Tae-Hwan Kim1,2, Jae-Bum Jun1,2, Wan-Sik Uhm1,2

Department of Internal Medicine, Hanyang University College of Medicine1, Department of Rheumatology, Hanyang University Hospital for Rheumatic Disease2, Seoul, Korea

Correspondence to : Wan-Sik Uhm

Abstract

Behçet's disease (BD) is a multisystemic disorder, which is characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesion. Although intestinal involvement is an uncommon manifestation of the BD, it leads to a poor prognosis, as a result of a high complication, such as intestinal perforation, fistula formation, and massive hemorrhage. Intestinal BD has the tendency for the resistance to conventional medical treatment, and it often requires a surgical intervention because of severe complication. Although the causes of intestinal BD are unknown, some studies show that tumor necrosis factor Alpha (TNF-Ձ) plays a key role in the pathogenesis of BD. Therefore, anti-TNF-Ձ monoclonal antibody, such as adalimumab, is one of the useful treatment for refractory and relapsed intestinal BD. We describe a patient who had intestinal BD complicated enterocutanous fistula with a good response to adalimumab.

Keywords Behçet's disease, Intestine, TNF-Ձ, Adalimumab

Article

Case Report

J Rheum Dis 2012; 19(3): 147-151

Published online June 30, 2012

Copyright © Korean College of Rheumatology.

장피부 누공을 동반한 베체트 장염 환자를 Adalimumab으로 치료한 1예

오일환1ㆍ김진옥1ㆍ변영재1ㆍ성윤경1,2ㆍ최찬범1,2ㆍ김태환1,2ㆍ전재범1,2ㆍ엄완식1,2

한양대학교 의과대학 내과학교실1, 류마티스병원 류마티스내과2

A Case of Intestinal Behçet's Disease Complicated Enterocutanous Fistula with a Good Response to Adalimumab

IL Hwan Oh1, Jin Ok Kim1, Young Jae Byun1, Yoon-Kyoung Sung1,2, Chan-Bum Choi1,2, Tae-Hwan Kim1,2, Jae-Bum Jun1,2, Wan-Sik Uhm1,2

Department of Internal Medicine, Hanyang University College of Medicine1, Department of Rheumatology, Hanyang University Hospital for Rheumatic Disease2, Seoul, Korea

Correspondence to:Wan-Sik Uhm

Abstract

Behçet's disease (BD) is a multisystemic disorder, which is characterized by recurrent oral aphthous ulcers, genital ulcers, uveitis, and skin lesion. Although intestinal involvement is an uncommon manifestation of the BD, it leads to a poor prognosis, as a result of a high complication, such as intestinal perforation, fistula formation, and massive hemorrhage. Intestinal BD has the tendency for the resistance to conventional medical treatment, and it often requires a surgical intervention because of severe complication. Although the causes of intestinal BD are unknown, some studies show that tumor necrosis factor Alpha (TNF-Ձ) plays a key role in the pathogenesis of BD. Therefore, anti-TNF-Ձ monoclonal antibody, such as adalimumab, is one of the useful treatment for refractory and relapsed intestinal BD. We describe a patient who had intestinal BD complicated enterocutanous fistula with a good response to adalimumab.

Keywords: Behç,et's disease, Intestine, TNF-Ձ,, Adalimumab

JRD
Jan 01, 2025 Vol.32 No.1, pp. 1~7
COVER PICTURE
Cumulative growth of rheumatology members and specialists (1980~2024). Cumulative distribution of the number of the (A) Korean College of Rheumatology members and (B) rheumatology specialists. (J Rheum Dis 2025;32:63-65)

Stats or Metrics

Share this article on

  • line

Related articles in JRD

Journal of Rheumatic Diseases

pISSN 2093-940X
eISSN 2233-4718
qr-code Download